Skip to main content
Top
Published in: Heart and Vessels 2/2014

01-03-2014 | Original Article

Atrial endothelial impairment through Toll-like receptor 4 signaling causes atrial thrombogenesis

Authors: Shigehiko Katoh, Shintaro Honda, Tetsu Watanabe, Satoshi Suzuki, Mitsunori Ishino, Tatsuro Kitahara, Akira Funayama, Shunsuke Netsu, Toshiki Sasaki, Tetsuro Shishido, Takuya Miyamoto, Mitsuaki Sadahiro, Isao Kubota

Published in: Heart and Vessels | Issue 2/2014

Login to get access

Abstract

Low-grade inflammation associated with heart failure (HF) is known to deteriorate cardioembolic stroke in patients with atrial fibrillation (AF). Little is known about the relationship between atrial endothelial impairment induced by innate immunity and thrombus formation. We examined whether atrial endothelial impairment through Toll-like receptor (TLR) 4 signaling causes atrial thrombogenesis. TLR4, heat shock protein 60, and vascular cell adhesion molecule (VCAM)-1 expression were higher in the atrium of AF patients who underwent valve replacement surgery with HF compared with those without it (p < 0.05). We created thoracic transverse aortic constriction (TAC) in TLR4 knock-out (KO) and wild-type (WT) mice. Atrial thrombosis was observed less frequently in TLR4 KO mice (4/15) than in WT mice (16/20) 4 weeks after TAC despite similar severity of heart failure. The decrease in endothelial nitric oxide synthase (eNOS) phosphorylation and increase in VCAM-1 and plasminogen activator inhibitor (PAI)-1 expression, observed in the atrium of WT mice following TAC, were significantly attenuated in TLR4 KO mice (p < 0.05). Nuclear factor-κB (NF-κB) activation after TAC was attenuated in TLR4 KO mice compared with WT mice. Activation of mitogen-activated protein kinase p38 (p38) after TAC was also attenuated in TLR4 KO mice (p < 0.05). Thus, increased VCAM-1 and PAI-1, and decreased eNOS phosphorylation through the TLR4/NFκB/p38 pathway, may be associated with atrial thrombogenesis in the heart failure mice model. Atrial endothelial impairment through the TLR4 signaling may play a role in atrial thrombogenesis in AF patients with HF.
Literature
1.
go back to reference Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952PubMedCrossRef Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952PubMedCrossRef
2.
go back to reference Acosta S, Ogren M, Bengtsson H, Bergqvist D, Lindblad B, Zdanowski Z (2006) Increasing incidence of ruptured abdominal aortic aneurysm: a population-based study. J Vasc Surg 44:237–243PubMedCrossRef Acosta S, Ogren M, Bengtsson H, Bergqvist D, Lindblad B, Zdanowski Z (2006) Increasing incidence of ruptured abdominal aortic aneurysm: a population-based study. J Vasc Surg 44:237–243PubMedCrossRef
3.
go back to reference Maisel AS, Nakao K, Ponikowski P, Peacock WF, Yoshimura M, Suzuki T, Tsutamoto T, Filippatos GS, Saito Y, Seino Y, Minamino N, Hirata Y, Mukoyama M, Nishikimi T, Nagai R (2011) Japanese-Western consensus meeting on biomarkers. Int Heart J 52:253–265PubMedCrossRef Maisel AS, Nakao K, Ponikowski P, Peacock WF, Yoshimura M, Suzuki T, Tsutamoto T, Filippatos GS, Saito Y, Seino Y, Minamino N, Hirata Y, Mukoyama M, Nishikimi T, Nagai R (2011) Japanese-Western consensus meeting on biomarkers. Int Heart J 52:253–265PubMedCrossRef
5.
go back to reference Yamashita T, Sekiguchi A, Iwasaki YK, Sagara K, Hatano S, Iinuma H, Aizawa T, Fu LT (2003) Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 108:2450–2452PubMedCrossRef Yamashita T, Sekiguchi A, Iwasaki YK, Sagara K, Hatano S, Iinuma H, Aizawa T, Fu LT (2003) Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 108:2450–2452PubMedCrossRef
6.
go back to reference Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwohner M, Strugala D, Pfeiffenberger J, Rohl FW, Huth C, Ebert MP, Klein HU, Rocken C (2008) Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 117:732–742PubMedCrossRef Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwohner M, Strugala D, Pfeiffenberger J, Rohl FW, Huth C, Ebert MP, Klein HU, Rocken C (2008) Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 117:732–742PubMedCrossRef
7.
go back to reference Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:263–272PubMedCrossRef Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:263–272PubMedCrossRef
8.
go back to reference Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:2886–2891PubMedCrossRef Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:2886–2891PubMedCrossRef
9.
go back to reference Conway DS, Buggins P, Hughes E, Lip GY (2004) Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 43:2075–2082PubMedCrossRef Conway DS, Buggins P, Hughes E, Lip GY (2004) Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 43:2075–2082PubMedCrossRef
10.
go back to reference Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K, Tamada Y, Kubota I (2005) C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 20:45–49PubMedCrossRef Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K, Tamada Y, Kubota I (2005) C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 20:45–49PubMedCrossRef
11.
go back to reference Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 13:308–328PubMedCrossRef Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 13:308–328PubMedCrossRef
12.
go back to reference Pedersen OD, Bagger H, Kober L, Torp-Pedersen C (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376–380PubMedCrossRef Pedersen OD, Bagger H, Kober L, Torp-Pedersen C (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376–380PubMedCrossRef
13.
go back to reference Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107:2926–2931PubMedCrossRef Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107:2926–2931PubMedCrossRef
14.
go back to reference Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ (2005) Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45:1832–1839PubMedCrossRef Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ (2005) Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45:1832–1839PubMedCrossRef
15.
go back to reference Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:712–719PubMedCrossRef Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:712–719PubMedCrossRef
16.
go back to reference Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA (1999) Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104:271–280PubMedCentralPubMedCrossRef Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA (1999) Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104:271–280PubMedCentralPubMedCrossRef
17.
go back to reference Eißler R, Schmaderer C, Rusai K, Kühne L, Sollinger D, Lahmer T, Witzke O, Lutz J, Heemann U, Baumann M (2011) Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res 34:551–558PubMedCrossRef Eißler R, Schmaderer C, Rusai K, Kühne L, Sollinger D, Lahmer T, Witzke O, Lutz J, Heemann U, Baumann M (2011) Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res 34:551–558PubMedCrossRef
18.
go back to reference Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347:185–192PubMedCrossRef Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347:185–192PubMedCrossRef
19.
go back to reference Ohashi K, Burkart V, Flohe S, Kolb H (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol 164:558–561PubMed Ohashi K, Burkart V, Flohe S, Kolb H (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol 164:558–561PubMed
20.
go back to reference Schafler AE, Kirmanoglou K, Balbach J, Pecher P, Hannekum A, Schumacher B (2002) The expression of heat shock protein 60 in myocardium of patients with chronic atrial fibrillation. Basic Res Cardiol 97:258–261PubMedCrossRef Schafler AE, Kirmanoglou K, Balbach J, Pecher P, Hannekum A, Schumacher B (2002) The expression of heat shock protein 60 in myocardium of patients with chronic atrial fibrillation. Basic Res Cardiol 97:258–261PubMedCrossRef
21.
go back to reference McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446PubMedCrossRef McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446PubMedCrossRef
22.
go back to reference Burke MA, Cotts WG (2007) Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev 12:23–36PubMedCrossRef Burke MA, Cotts WG (2007) Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev 12:23–36PubMedCrossRef
23.
go back to reference Sadanaga T, Kohsaka S, Mitamura H, Ogawa S (2011) Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels 26:530–535PubMedCrossRef Sadanaga T, Kohsaka S, Mitamura H, Ogawa S (2011) Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels 26:530–535PubMedCrossRef
24.
go back to reference Tamura H, Watanabe T, Nishiyama S, Sasaki S, Wanezaki M, Arimoto T, Takahashi H, Shishido T, Miyashita T, Miyamoto T, Hirono O, Kayama T, Kubota I (2012) Elevated plasma brain natriuretic peptide levels predict left atrial appendage dysfunction in patients with acute ischemic stroke. J Cardiol 60:126–132PubMedCrossRef Tamura H, Watanabe T, Nishiyama S, Sasaki S, Wanezaki M, Arimoto T, Takahashi H, Shishido T, Miyashita T, Miyamoto T, Hirono O, Kayama T, Kubota I (2012) Elevated plasma brain natriuretic peptide levels predict left atrial appendage dysfunction in patients with acute ischemic stroke. J Cardiol 60:126–132PubMedCrossRef
25.
go back to reference Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S (1999) Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 11:443–451PubMedCrossRef Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S (1999) Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 11:443–451PubMedCrossRef
26.
go back to reference Harada M, Takeishi Y, Arimoto T, Niizeki T, Kitahara T, Goto K, Walsh RA, Kubota I (2007) Diacylglycerol kinase zeta attenuates pressure overload-induced cardiac hypertrophy. Circ J 71:276–282PubMedCrossRef Harada M, Takeishi Y, Arimoto T, Niizeki T, Kitahara T, Goto K, Walsh RA, Kubota I (2007) Diacylglycerol kinase zeta attenuates pressure overload-induced cardiac hypertrophy. Circ J 71:276–282PubMedCrossRef
27.
go back to reference Niizeki T, Takeishi Y, Kitahara T, Arimoto T, Ishino M, Bilim O, Suzuki S, Sasaki T, Nakajima O, Walsh RA, Goto K, Kubota I (2008) Diacylglycerol kinase-epsilon restores cardiac dysfunction under chronic pressure overload: a new specific regulator of Galpha(q) signaling cascade. Am J Physiol Heart Circ Physiol 295:H245–H255PubMedCrossRef Niizeki T, Takeishi Y, Kitahara T, Arimoto T, Ishino M, Bilim O, Suzuki S, Sasaki T, Nakajima O, Walsh RA, Goto K, Kubota I (2008) Diacylglycerol kinase-epsilon restores cardiac dysfunction under chronic pressure overload: a new specific regulator of Galpha(q) signaling cascade. Am J Physiol Heart Circ Physiol 295:H245–H255PubMedCrossRef
28.
go back to reference Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle E, Yu X, Kupershmidt S, Roden DM, Wagner T, Yatani A, Vatner DE, Vatner SF, Sadoshima J (2005) Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 115:3045–3056PubMedCentralPubMedCrossRef Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle E, Yu X, Kupershmidt S, Roden DM, Wagner T, Yatani A, Vatner DE, Vatner SF, Sadoshima J (2005) Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 115:3045–3056PubMedCentralPubMedCrossRef
29.
go back to reference Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M (2005) Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 11:1330–1338PubMedCrossRef Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M (2005) Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 11:1330–1338PubMedCrossRef
30.
go back to reference Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, Salama G, McTiernan CF, London B (2005) Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol 289:H1456–H1467PubMedCrossRef Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, Salama G, McTiernan CF, London B (2005) Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol 289:H1456–H1467PubMedCrossRef
31.
go back to reference Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, Lisy O, Miller V, Simari RD, Burnett JC Jr (2000) Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol 35:796–801PubMedCrossRef Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, Lisy O, Miller V, Simari RD, Burnett JC Jr (2000) Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol 35:796–801PubMedCrossRef
32.
go back to reference Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A, Egido J (2011) Animal models of cardiovascular diseases. J Biomed Biotechnol 2011:497841PubMedCentralPubMedCrossRef Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A, Egido J (2011) Animal models of cardiovascular diseases. J Biomed Biotechnol 2011:497841PubMedCentralPubMedCrossRef
33.
go back to reference Matsumoto K, Ogawa M, Suzuki J, Hirata Y, Nagai R, Isobe M (2011) Regulatory T lymphocytes attenuate myocardial infarction-induced ventricular remodeling in mice. Int Heart J 52:382–387PubMedCrossRef Matsumoto K, Ogawa M, Suzuki J, Hirata Y, Nagai R, Isobe M (2011) Regulatory T lymphocytes attenuate myocardial infarction-induced ventricular remodeling in mice. Int Heart J 52:382–387PubMedCrossRef
34.
go back to reference Saito T, Watanabe M, Kojima T, Matsumura T, Fujita H, Kiyosue A, Takahashi M, Takeda N, Maemura K, Yamashita H, Hirata Y, Komatsu S, Ohtomo K, Nagai R (2011) Successful blood sampling through azygos continuation with interrupted inferior vena cava. A case report and review of the literature. Int Heart J 52:327–330PubMedCrossRef Saito T, Watanabe M, Kojima T, Matsumura T, Fujita H, Kiyosue A, Takahashi M, Takeda N, Maemura K, Yamashita H, Hirata Y, Komatsu S, Ohtomo K, Nagai R (2011) Successful blood sampling through azygos continuation with interrupted inferior vena cava. A case report and review of the literature. Int Heart J 52:327–330PubMedCrossRef
35.
go back to reference Annambhotla S, Bourgeois S, Wang X, Lin PH, Yao Q, Chen C (2008) Recent advances in molecular mechanisms of abdominal aortic aneurysm formation. World J Surg 32:976–986PubMedCentralPubMedCrossRef Annambhotla S, Bourgeois S, Wang X, Lin PH, Yao Q, Chen C (2008) Recent advances in molecular mechanisms of abdominal aortic aneurysm formation. World J Surg 32:976–986PubMedCentralPubMedCrossRef
36.
go back to reference Lin KM, Lin B, Lian IY, Mestril R, Scheffler IE, Dillmann WH (2001) Combined and individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths induced by simulated ischemia-reoxygenation. Circulation 103:1787–1792PubMedCrossRef Lin KM, Lin B, Lian IY, Mestril R, Scheffler IE, Dillmann WH (2001) Combined and individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths induced by simulated ischemia-reoxygenation. Circulation 103:1787–1792PubMedCrossRef
37.
go back to reference Gupta S, Knowlton AA (2002) Cytosolic heat shock protein 60, hypoxia, and apoptosis. Circulation 106:2727–2733PubMedCrossRef Gupta S, Knowlton AA (2002) Cytosolic heat shock protein 60, hypoxia, and apoptosis. Circulation 106:2727–2733PubMedCrossRef
38.
go back to reference Kol A, Bourcier T, Lichtman AH, Libby P (1999) Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103:571–577PubMedCentralPubMedCrossRef Kol A, Bourcier T, Lichtman AH, Libby P (1999) Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103:571–577PubMedCentralPubMedCrossRef
39.
go back to reference Kol A, Sukhova GK, Lichtman AH, Libby P (1998) Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 98:300–307PubMedCrossRef Kol A, Sukhova GK, Lichtman AH, Libby P (1998) Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 98:300–307PubMedCrossRef
40.
go back to reference Daugherty A, Manning MW, Cassis LA (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105:1605–1612PubMedCentralPubMedCrossRef Daugherty A, Manning MW, Cassis LA (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105:1605–1612PubMedCentralPubMedCrossRef
41.
go back to reference Law MR, Frost CD, Wald NJ (1991) By how much does dietary salt reduction lower blood pressure? I—analysis of observational data among populations. BMJ 302:811–815PubMedCentralPubMedCrossRef Law MR, Frost CD, Wald NJ (1991) By how much does dietary salt reduction lower blood pressure? I—analysis of observational data among populations. BMJ 302:811–815PubMedCentralPubMedCrossRef
42.
go back to reference Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, William Browder I, Kao RL, Li C (2005) Reduced cardiac hypertrophy in Toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 68:224–234PubMedCrossRef Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, William Browder I, Kao RL, Li C (2005) Reduced cardiac hypertrophy in Toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 68:224–234PubMedCrossRef
43.
go back to reference Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, Van Middelaar BJ, Pasterkamp G, Quax PH, De Kleijn DP (2004) Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109:393–398PubMedCrossRef Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, Van Middelaar BJ, Pasterkamp G, Quax PH, De Kleijn DP (2004) Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109:393–398PubMedCrossRef
44.
go back to reference Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW (2007) Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 100:1589–1596PubMedCrossRef Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW (2007) Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 100:1589–1596PubMedCrossRef
45.
go back to reference Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, Esmon CT (2011) Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 118:1952–1961PubMedCentralPubMedCrossRef Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, Esmon CT (2011) Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 118:1952–1961PubMedCentralPubMedCrossRef
46.
go back to reference Traub O, Berk BC (1998) Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 18:677–685PubMedCrossRef Traub O, Berk BC (1998) Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 18:677–685PubMedCrossRef
47.
go back to reference Yang QW, Mou L, Lv FL, Wang JZ, Wang L, Zhou HJ, Gao D (2005) Role of Toll-like receptor 4/NF-kappaB pathway in monocyte-endothelial adhesion induced by low shear stress and ox-LDL. Biorheology 42:225–236PubMed Yang QW, Mou L, Lv FL, Wang JZ, Wang L, Zhou HJ, Gao D (2005) Role of Toll-like receptor 4/NF-kappaB pathway in monocyte-endothelial adhesion induced by low shear stress and ox-LDL. Biorheology 42:225–236PubMed
48.
go back to reference Li YH, Lai LP, Shyu KG, Hwang JJ, Ma HM, Ko YL, Kuan P, Lien WP (1994) Clinical implications of left atrial appendage function: its influence on thrombus formation. Int J Cardiol 43:61–66PubMedCrossRef Li YH, Lai LP, Shyu KG, Hwang JJ, Ma HM, Ko YL, Kuan P, Lien WP (1994) Clinical implications of left atrial appendage function: its influence on thrombus formation. Int J Cardiol 43:61–66PubMedCrossRef
Metadata
Title
Atrial endothelial impairment through Toll-like receptor 4 signaling causes atrial thrombogenesis
Authors
Shigehiko Katoh
Shintaro Honda
Tetsu Watanabe
Satoshi Suzuki
Mitsunori Ishino
Tatsuro Kitahara
Akira Funayama
Shunsuke Netsu
Toshiki Sasaki
Tetsuro Shishido
Takuya Miyamoto
Mitsuaki Sadahiro
Isao Kubota
Publication date
01-03-2014
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 2/2014
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-013-0369-3

Other articles of this Issue 2/2014

Heart and Vessels 2/2014 Go to the issue